Candidate: Antibodies targeting SARS-CoV-2
Type: Therapeutic antibody candidates from Twist that bind with high affinity to either SARS-CoV-2 S1 spike protein or the human ACE2 cellular receptor, using Serimmune’s Serum Epitope Repertoire Analysis (SERA) platform, designed to map the antigenic targets of antibody repertoires.
Status: Twist Bioscience and Serimmune said June 9 they will partner to identify and evaluate SARS-CoV-2 therapeutic antibody candidates from Twist libraries using Serimmune’s SERA platform. “Serimmune’s platform will allow us to accelerate our efforts in a targeted and methodical manner to further increase the specificity of our antibodies, continuing our sprint in delivering new therapeutics to treat COVID-19,” Twist CEO and co-founder Emily Leproust, PhD, said in a statement.
Epitopes identified in the first phase will be used to re-screen Twist’s proprietary synthetic antibody discovery libraries to identify and evaluate new candidates—and to further increase the specificity of antibody candidates. Twist agreed to oversee advancement of all antibodies resulting from the collaboration.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: